Ophthalmology

Top Story

Reading speed suitable outcome measure for lampalizumab trials

Reading speed suitable outcome measure for lampalizumab trials
February 11, 2016

MIAMI — Results of the MAHALO study support the use of reading speed as a secondary outcome measure in clinical trials for lampalizumab, a speaker told colleagues here.

Lampalizumab (Roche) is a monoclonal antibody fragment that targets factor D and inhibits the progression of geographic atrophy.

Lindstrom's PerspectivePublication Exclusive

Disruptive changes ahead in glaucoma space

Ocular Surgery News U.S. Edition, February 25, 2016
Richard L. Lindstrom, MD
All of us who do cataract surgery see a significant number of patients who have glaucoma as a comorbidity. At least 10% of patients who come to have cataract surgery…
Back to BasicsPublication Exclusive

Working with industry as a speaker, investigator and consultant

Ocular Surgery News U.S. Edition, February 25, 2016
Uday Devgan, MD
Over the past dozen years, I have enjoyed working with many ophthalmic companies to design new devices, evaluate and improve current products, and educate fellow…
CEDARS/ASPENS DebatesPublication Exclusive

YAG laser vitreolysis vs. pars plana vitrectomy for vitreous floaters

Ocular Surgery News U.S. Edition, February 25, 2016
Karl G. Stonecipher, MD; Adam A. Carver, MD; Schachar Tauber, MD
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the…

Letter to the Editor

Ocular Surgery News U.S. Edition, February 25, 2016
To the Editor:I am submitting a counterpoint to the apologetics provided by Drs. Gustafson and Lindstrom regarding the pricing of Omidria in the Nov. 10, 2015, issue…
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina, March 2015, Volume 46 Issue 3
More »
CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Featured
Meeting News CoverageVideo

VIDEO: Allergan looks to have complete platform for glaucoma treatment

February 9, 2016
More »
morganatic-roan
morganatic-roan